Literature DB >> 15368109

Percutaneous transhepatic papillary balloon dilation as a therapeutic option for choledocholithiasis.

Ikuo Nagashima1, Tadahiro Takada, Masatoshi Shiratori, Tsuyoshi Inaba, Kota Okinaga.   

Abstract

BACKGROUND: For choledocholithiasis, endoscopic therapy, including endoscopic sphincterotomy (EST) or endoscopic papillary balloon dilation (EPBD), is now standard. However, the procedure of endoscopic therapy is very complicated and sometimes incomplete for reasons of anatomical anomalies. Therefore, we started performing percutaneous transhepatic papillary balloon dilations (PTPBD) instead of endoscopic therapy for choledocholithiasis 1 year ago for some selected patients. We report our technical methods of PTPBD.
METHODS: First, percutaneous transhepatic cholangiodrainage (PTCD) was performed under ultrasound guidance. Via the drainage route, the balloon catheter was inserted until the common bile duct was reached. Then, cholangiography was performed and the stones were identified. The balloon was maintained in the inflated state with 4 ml air at the papilla of Vater for 3 min. Next, the stones were pushed out rapidly into the duodenum with the same balloon catheter. If the stone diameter was larger than 8 mm, then basket lithotripsy was performed before balloon dilation.
RESULTS: Five patients underwent PTPBDs. The bile duct stones were successfully pushed out into the duodenum in all patients. The first three patients required two sessions for complete stone clearance due to technical problems; however, the last two patients needed only one session. There were no deaths and no complications.
CONCLUSIONS: We recommend that PTPBD might be a feasible and alternative therapeutic option for choledocholithiasis.

Entities:  

Mesh:

Year:  2004        PMID: 15368109     DOI: 10.1007/s00534-003-0851-x

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  8 in total

Review 1.  Choledocholithiasis: Evaluation, Treatment, and Outcomes.

Authors:  Christopher Molvar; Bryan Glaenzer
Journal:  Semin Intervent Radiol       Date:  2016-12       Impact factor: 1.513

Review 2.  Choledocholithiasis: evolving standards for diagnosis and management.

Authors:  Marilee-L Freitas; Robert-L Bell; Andrew-J Duffy
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 3.  Balloon dilation itself may not be a major determinant of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Sung Ill Jang; Gak Won Yun; Dong Ki Lee
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

4.  Laparoscopy-Assisted Trans-Gastric Rendez-vous for the Treatment of Common Bile Duct Stones in Patients with Prior Roux-en-Y Gastric Bypass.

Authors:  Ricardo Mejía; Pablo Achurra; Mauricio Gabrielli; Eduardo Briceño; Rolando Rebolledo; Alberto Torres; Allan Sharp; Fernando Pimentel; Fernando Crovari
Journal:  Obes Surg       Date:  2016-11       Impact factor: 4.129

5.  Video. Laparoscopic transgastric access to the common bile duct after Roux-en-Y gastric bypass.

Authors:  G Dapri; J Himpens; M Buset; G Vasilikostas; R Ntounda; G B Cadière
Journal:  Surg Endosc       Date:  2009-04-03       Impact factor: 4.584

6.  Percutaneous transhepatic cholangiography for choledocholithiasis after laparoscopic gastric bypass surgery.

Authors:  Marialessia Milella; Maryam Alfa-Wali; Luca Leuratti; James McCall; Gianluca Bonanomi
Journal:  Int J Surg Case Rep       Date:  2014-03-12

Review 7.  Review of the Endoscopic, Surgical and Radiological Techniques of Treating Choledocholithiasis in Bariatric Roux-en-Y Gastric Bypass Patients and Proposed Management Algorithm.

Authors:  Qiuye Cheng; Amy Hort; Peter Yoon; Ken Loi
Journal:  Obes Surg       Date:  2021-08-05       Impact factor: 3.479

8.  Various techniques for the surgical treatment of common bile duct stones: a meta review.

Authors:  Abolfazl Shojaiefard; Majid Esmaeilzadeh; Ali Ghafouri; Arianeb Mehrabi
Journal:  Gastroenterol Res Pract       Date:  2009-08-06       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.